Interestingly, [177Lu]Lu-DOTAGA-GARP also induced a significant decrease in Tregs and GARP+ Tregs in tumours compared with [177Lu]Lu-DOTAGA-Ig (Supplemental Fig. 5), thus confirming an active targeting of GARP by [177Lu]Lu-DOTAGA-GARP. Here, LRRC32 is linked to neoplasm.